

UCLA

UCLA Previously Published Works

Title

Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms

Permalink

<https://escholarship.org/uc/item/8dj8d587>

Journal

Gastroenterology, 158(5)

ISSN

0016-5085

Authors

Delshad, Sean D

Almario, Christopher V

Chey, William D

et al.

Publication Date

2020-04-01

DOI

10.1053/j.gastro.2019.12.014

Peer reviewed



HHS Public Access

Author manuscript

Gastroenterology. Author manuscript; available in PMC 2021 April 01.

Published in final edited form as:

Gastroenterology. 2020 April ; 158(5): 1250–1261.e2. doi:10.1053/j.gastro.2019.12.014.

Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms

Sean D. Delshad, MD, MBA^{1,2}, Christopher V. Almario, MD, MSHPM^{1,3,4,5}, William D. Chey, MD⁶, Brennan M.R. Spiegel, MD, MSHS^{1,3,4}

¹Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Los Angeles, CA

²Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

³Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA

⁴Division of Health Services Research, Cedars-Sinai Medical Center, Los Angeles, CA

⁵Division of Informatics, Cedars-Sinai Medical Center, Los Angeles, CA

⁶Division of Gastroenterology, Michigan Medicine, Ann Arbor, MI

Abstract

BACKGROUND & AIMS: There are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United States. We performed a population-based study to determine the prevalence of GERD symptoms and persistent GERD symptoms despite use of proton pump inhibitors (PPIs).

METHODS: We conducted the National Gastrointestinal Survey in 2015 using MyGiHealth, an app that guides participants through National Institutes of Health gastrointestinal PROMIS

CORRESPONDENCE: Brennan M.R. Spiegel, MD, MSHS, Professor-in-Residence of Medicine and Public Health, Cedars-Sinai Medical Center, Director, Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Director, Health Services Research, Cedars-Sinai Health System, 116 North Robertson Boulevard, 8th Floor, Los Angeles, California 90048, Brennan.Spiegel@cshs.org, Office Phone: (310) 423-6467.

AUTHOR CONTRIBUTIONS:

- Sean D. Delshad, MD, MBA: study design; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content.
- Christopher V. Almario, MD, MSHPM: study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; study supervision.
- William D. Chey, MD: study concept and design; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; study supervision.
- Brennan M.R. Spiegel, MD, MSHS: study concept and design; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; study supervision.

*These authors share co-first authorship.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

DISCLOSURES: Brennan M.R. Spiegel and William D. Chey are consultants for Ironwood Pharmaceuticals and patent holders and principals at My Total Health. Christopher V. Almario has a stock option grant in My Total Health. Sean D. Delshad does not have any relevant disclosures.

WRITING ASSISTANCE: None.


surveys. Primary outcomes were prevalence of GERD symptoms in the past and persistence of GERD symptoms (heartburn or regurgitation 2 or more days in past week) among participants taking PPIs. Population weights were applied to the data and multivariable regression was used to adjust for confounding.

RESULTS: Among 71,812 participants, 32,878 (44.1%) reported having had GERD symptoms in the past and 23,039 (30.9%) reported having GERD symptoms in the last week. We also found that 35.1% of those who had experienced GERD symptoms were currently on therapy (55.2% on PPIs, 24.3% on histamine-2 receptor blockers, and 24.4% on antacids). Among 3,229 participants taking daily PPIs, 54.1% had persistent GERD symptoms. Younger individuals, women, Latinos, and participants with irritable bowel syndrome or Crohn's disease were more likely to have continued symptoms, even when taking PPIs.

CONCLUSIONS: Using a population-based survey, we found GERD symptoms to be common: 2 of 5 participants have had GERD symptoms in the past and 1 of 3 had symptoms in the last week. We also found that half of PPI users have persistent symptoms. Given the significant effect of GERD on quality of life, further research and development of new therapies are needed for patients with PPI-refractory GERD symptoms.

GRAPHICAL ABSTRACT

Results of a Survey of 71,812 Persons in the United States



LAY SUMMARY

In a survey of residents of the United States, almost one-third had symptoms of gastroesophageal reflux in the past week. Half of users of proton pump inhibitors have persistent symptoms; new treatments are needed.

Keywords

heartburn; regurgitation; esophagus; North America

INTRODUCTION

Gastroesophageal reflux disease (GERD) involves classic symptoms of heartburn and/or regurgitation.¹ It is a highly prevalent disease with significant economic impact and reduction in patient health-related quality of life.²⁻⁵ Although there are a number of available effective prescription and over-the-counter therapies, 45% of patients on a proton pump inhibitor (PPI) experience persistent GERD symptoms despite treatment.⁶

Previous estimates of the prevalence of weekly GERD symptoms in the US range from 18% to 28%.⁷ These estimates, however, are based largely on two populations: residents of Olmstead County, Minnesota, and employees of the Houston Veterans Affairs (VA) Medical Center.⁷ Neither group is representative of the current US demographics as Olmstead County is 90% Caucasian⁷ and the Houston VA employee population is 43% African American.⁸ Another US population-based study of 21,128 adults found that 22% and 16% of Americans experienced heartburn and regurgitation within the past month, respectively.⁹ Of note, while this study was conducted nationally, the cohort was 82% non-Hispanic white; data from the US Census Bureau's American Community Survey in 2017 shows that 61% of the population is non-Hispanic white.¹⁰ As GERD prevalence varies with race/ethnicity, these prior studies may provide inaccurate estimates of the current prevalence of GERD symptoms in the US.¹¹

Given the significant impact of heartburn and regurgitation on health-related quality of life and healthcare utilization along with the evolving demographics of the US, it is important to understand the current burden and distribution of GERD symptoms in the US population. Moreover, the high prevalence of persistent GERD symptoms despite PPI therapy (referred to as 'PPI-refractory GERD symptoms' in this paper) also highlights the need for a better understanding of the predictors of the disease and response to therapies as we aim to reduce its overall burden and maximize benefits from future adjunctive, novel therapies. Therefore, the aims of this study were to determine the prevalence and predictors of GERD and PPI-refractory GERD symptoms in a large, representative sample of community-dwelling Americans.

MATERIALS AND METHODS

Study Design, Data Source, and Study Population

In October 2015 our group conducted the "National Gastrointestinal (GI) Survey," a population-based audit of GI symptoms in over 71,000 community-dwelling Americans.^{12–15} The survey was administered via *MyGiHealth*, a mobile app that utilizes AEGIS (Automated Evaluation of GI Symptoms), an automated algorithm that has previously been described in detail.¹⁶ AEGIS asked users to "Select any symptom(s) you experienced in the past week" and "Please check any of these GI symptom(s) that you have EVER experienced." Answer options included the following eight symptoms as well as a "none of these" option: heartburn, acid reflux, or gastroesophageal reflux; abdominal pain; bloating/gas; constipation; diarrhea; disrupted swallowing; fecal incontinence; nausea and vomiting. We chose these symptoms based on the National Institutes of Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS) framework.^{17–19} For each reported GI symptom, AEGIS guided respondents through corresponding GI PROMIS questionnaires to measure severity²⁰; the GERD PROMIS item bank and other questions related to "heartburn, acid reflux, or gastroesophageal reflux" are presented in the Supplementary File. Participants were also presented questions regarding demographics, socioeconomic status, and medical comorbidities.

We aimed to recruit a representative sample of Americans for the National GI Survey by enacting quotas for age, sex, and region of country (Northeast, South, Midwest, and West).

We partnered with Cint, a survey research firm that utilizes a reward system to incentivize respondents to participate in surveys. Potential respondents were sent an email through Cint research panels inviting them to complete an online survey. Along with the link to the survey, the email also included the following templated text, which was subject to editing from individual research panels: “Based on the information stored in your [research panel] profile, we believe we have a survey that you will qualify & earn from. The survey takes approximately 15 minutes and if you successfully complete it, your account will be credited with [incentive].” Cint’s reward symptom is based on the length of the interview and requires certain thresholds to be met before panelists can redeem rewards. This structure is meant to encourage long-term participation and discourage professional respondents who seek to take surveys only for financial gain.

Participant recruitment for the National GI Survey occurred from October 14, 2015 to November 4, 2015. Survey initiations were distributed by Cint until we reached our sample size goal of approximately 70,000 respondents, allowing us to create a dataset with robust explanatory power and for examining the prevalence and predictors of both common as well as less common GI symptoms. Users who clicked the survey link in the invitation were brought to a home page asking them to complete a “GI Survey”; no specific mentions of GERD were made on the initial screen. All individuals 18 years of age were included in the study.

Outcomes

Our primary outcome was prevalence of having had GERD symptoms (heartburn, acid reflux, or gastroesophageal reflux) in the past, categorized by having ever experienced GERD symptoms, GERD symptoms within the past 7 days, and troublesome GERD symptoms as determined by a modified Montreal definition (heartburn or regurgitation occurring 2 days in the last week).¹ To determine whether respondents met the Montreal definition, we leveraged 2 items from PROMIS (Supplementary File): heartburn: In the past 7 days, how often did you feel burning in the red area shown in the picture (behind the breastbone)?; and regurgitation: In the past 7 days, how often did you have regurgitation – that is food or liquid coming back into your throat or mouth without vomiting? Answer options for both questions included never, one day, 2–6 days, once a day, or more than once a day. Of note, while the Global Consensus Group states that in population-based studies troublesome GERD symptoms can be determined by the presence of mild symptoms on 2 days a week or moderate/severe symptoms occurring 1 day a week, our survey only assessed for the former, hence our use of a modified Montreal definition. As a secondary outcome, we assessed for GERD symptom severity as determined by PROMIS in those who reported GERD in the past week.^{13, 19, 20} Another secondary outcome was prevalence of PPI-refractory GERD symptoms, defined as heartburn or regurgitation for 2 days in the past week among those currently taking a daily PPI.

Covariates

We also examined participants’ medication use, demographics, and past medical history. Respondents were asked which medicines they were currently taking for their GERD symptoms and frequency of use (Supplementary File): PPI (dexlansoprazole, esomeprazole,

lansoprazole, omeprazole, pantoprazole, rabeprazole); histamine-2 receptor blocker (cimetidine, famotidine, ranitidine); antacids (e.g., Tums, Roloids, Mylanta, Maalox); other medicine. Demographic information elicited via the survey included age, gender, race/ethnicity, education, marital status, employment status, and income level. They were also asked to identify comorbid conditions that had been “diagnosed by a doctor and can affect the gastrointestinal system,” including irritable bowel syndrome (IBS), chronic idiopathic constipation, cancer of the GI tract, celiac disease, cirrhosis, Crohn’s disease, ulcerative colitis, diabetes, endometriosis, gallstones, HIV/AIDS, pancreatitis, peptic ulcer disease, and thyroid disease.

Statistical Analysis

All statistical analyses were performed in Stata 13.1 (StataCorp LP, College Station, TX). We used data from the 2010 US Census (age, sex) and 2015 US Census Bureau’s American Community Survey (race/ethnicity) to create population weights and applied them to the sample data to produce population estimates^{10, 21}; the actual weights used in the analyses were previously described elsewhere.^{13, 14} This was done to adjust for over- and under-sampling of subgroups in the National GI Survey, thereby decreasing bias due to nonresponse and underrepresented groups in the population.

A two-tailed p-value of less than .05 was considered statistically significant. We performed population-weighted (PW) multivariable regression models to adjust for potentially confounding factors and to calculate adjusted p-values, odds ratios (OR), and 95% confidence intervals (CI). These regression models were performed on our primary and secondary outcomes, adjusted by relevant demographic, socioeconomic medication, and comorbidity variables described above. We used logistic and linear multivariable regression models for binary and continuous outcomes, respectively. This study was approved by the Cedars-Sinai Institutional Review Board (Pro54744).

RESULTS

Study Cohort

In all, 1.3 million individuals were invited to complete the National GI Survey with the opportunity to participate in the study up until at least 70,000 surveys were completed. Ultimately, 124,674 (9.4%) individuals accessed the survey, of whom 71,812 (57.6%) completed the questionnaires and were included in the study. Table 1 lists the demographic information of the study cohort.

GERD Symptoms Within the Past 7 Days Among Overall Cohort

Among 71,812 participants, we found that 32,878 (PW 44.1%) had ever experienced GERD symptoms in the past and 23,039 (PW 30.9%) reported being symptomatic in the past week. Table 2 summarizes the predictors of having had GERD symptoms in the past week. When compared to individuals aged 18–29 years, those 30–59 years of age had increased odds for reporting recent esophageal symptoms; no significant difference was seen for the 60 year old group. Females and those who identified as non-Hispanic white were more likely to have had recent GERD symptoms. Increasing levels of education as well as non-single marital

status were associated with significantly higher odds for having experienced GERD symptoms in the past week. Individuals with income levels from \$50,001-\$100,000 were more likely to report recent GERD symptoms as compared to those with income levels \$50,000; conversely, those making \$200,001 were less likely to have such symptoms. Moreover, those with specific comorbidities, including IBS, Crohn's disease, diabetes, endometriosis, gallstones, peptic ulcer disease, and thyroid disease were also more likely to experience GERD symptoms within the past 7 days.

Troublesome GERD Symptoms (Modified Montreal Definition) Among Overall Cohort

We found that 13,881 (PW 18.0%) out of 71,812 individuals met the modified Montreal definition for troublesome GERD symptoms (heartburn or regurgitation for ≥ 2 days in the past week): heartburn only, 6,751 (PW 47.5%); both heartburn and regurgitation, 5,426 (PW 39.8%); regurgitation only, 1,704 (PW 12.6%). Table 2 presents findings from the regression on having Montreal-defined GERD symptoms. Similar to the regression on GERD symptoms in the past 7 days, female gender, non-single marital status, and total household income level from \$50,001-\$100,000 were associated with increased odds for having Montreal-defined GERD symptoms. However, unlike the prior analysis, only those 30–49 years of age had increased odds for troublesome GERD symptoms vs. those who were 18–29 years old; no difference was seen for the 50–59 year old group. Moreover, we also found that participants who were ≥ 60 years of age had decreased odds for Montreal-defined GERD symptoms when compared to 18–29 year olds. As for race/ethnicity, non-Hispanic blacks and Asians remained at lower odds for having bothersome symptoms vs. non-Hispanic whites, while no differences were seen for the Latino and other racial/ethnic groups. Education level, while predictive of GERD symptoms in the past week, was largely not associated with Montreal-defined GERD. With respect to specific comorbidities, those that were predictive of GERD in the past week remained positively associated with Montreal-defined GERD symptoms, with cirrhosis being a new addition.

GERD Symptom Severity Among Those who were Symptomatic in the Past 7 Days

We show findings from the regression on GERD PROMIS percentile scores among individuals who were symptomatic in the past week in Table 3. Latinos and Asians had significantly higher GERD PROMIS scores vs. non-Hispanic whites. Those who were non-single and had IBS, celiac disease, cirrhosis, Crohn's disease, diabetes, endometriosis, and thyroid disease also had more severe symptoms. Moreover, individuals who reported current PPI, histamine-2 receptor blocker, and antacid use also had worse symptoms. Conversely, increasing age, male gender, and higher education levels were associated with significantly lower GERD PROMIS scores.

GERD Medication Use

Among the 32,878 individuals who reported ever experiencing presumptive GERD, we had data on medication use from 29,274 respondents. Among the 29,274, we found that 9,234 individuals (PW 35.1%) were currently taking a medicine to manage their symptoms. Those on therapy reported taking the following: PPI, 4,935 (PW 55.2%); histamine-2 receptor blocker, 2,286 (PW 24.3%); antacids, 2,370 (PW 24.4%); other, 217 (PW 2.6%). Table 4 lists the frequency of use of each medicine class. Most of those on a PPI reported taking it

daily (PW 68.1%) whereas more intermittent use was noted among those using histamine-2 receptor blockers and antacids.

Persistent GERD Symptoms While on a Daily PPI

Among those taking a daily PPI (n=3,229), 1,858 (PW 54.1%) noted persistent, troublesome GERD symptoms (heartburn or regurgitation for ≥ 2 days in the past week). Symptomatic individuals reported the following symptoms even while on a PPI: both heartburn and regurgitation, 877 (PW 48.0%); heartburn only, 792 (PW 42.3%); regurgitation only, 189 (PW 9.7%).

Table 5 presents predictors of PPI-refractory GERD symptoms. Individuals who were younger, female, Latino, divorced, separated, widowed, or married, and had IBS and Crohn's disease had higher odds for remaining symptomatic while on a PPI. Conversely, those with GI cancer and ulcerative colitis were less likely to have PPI-refractory symptoms. No significant associations were largely seen between persistent symptoms and concomitant use of histamine-2 receptor blockers and antacids.

DISCUSSION

In this population-based survey, we found that GERD symptoms are very common in the community. More than 2 of 5 Americans have experienced heartburn or regurgitation in the past while nearly 1 of 3 experienced these symptoms in the last week. Additionally, among those managing their symptoms with a daily PPI, we found that more than half still have persistent, troublesome GERD symptoms.

Our prevalence of presumptive GERD is largely in line with prior estimates from other US cross-sectional and population-based studies. Namely, the prevalence of weekly GERD symptoms from past studies conducted in the 1990s and early 2000s ranged from 18% to 28% with a sample size-weighted mean of 20%,⁷ while we found that 31% of respondents in our study reported GERD symptoms in the past week. Although it is difficult to make direct comparisons in the prevalence rates given the varying definitions of GERD and different populations,⁷ our data suggests that the prevalence of GERD symptoms may be increasing.²² This increasing burden is likely related in large part to the obesity epidemic. At the time of the National GI Survey in 2015, approximately 40% of Americans were obese (as compared to 30% in 1999),^{23, 24} and obesity has been shown to increase the odds of GERD up to 3-fold.²⁵⁻²⁷ This is problematic as GERD leads to decrements in quality of life, mental health, and social function.²⁻⁴ It is also associated with significant healthcare utilization, as GERD is the second leading physician diagnosis among the GI disorders with more than 5.5 million office and emergency room visits in 2014.⁵

Aside from examining the prevalence of GERD symptoms in the past week, we also determined how many individuals in the community have such symptoms as determined by a modified Montreal definition¹; this allows for a more precise, criterion-definition of GERD. Here, we found that 18% of individuals reported either heartburn or regurgitation at least 2 days out of the week, which the Global Consensus Group considers troublesome. The prevalence of GERD symptoms using the modified Montreal definition is much higher in

our study than a previous US population study, which found that 6% and 3% of respondents experienced heartburn and regurgitation, respectively, at least twice per week.⁹ To our knowledge, the only other studies that employed the Montreal definition examined non-US populations, with prevalence rates of 3% and 16% in China²⁸ and Japan,²⁹ respectively. These rates are lower than that noted in our study, and the true difference is likely even more pronounced, as we used a modified Montreal definition that did not include moderate-to-severe symptoms of heartburn or regurgitation occurring 1 day a week; our study was only able to assess for those who had either symptom to any degree on 2 days a week.

In our study, we found a number of predictors of GERD symptoms. For instance, men were less likely to have had both GERD symptoms in the last week and Montreal-defined GERD when compared to women. Prior data in the literature has been equivocal on this point, as some studies indicate a higher prevalence of GERD in men, others in women, and others demonstrate no difference at all.^{30–32} Similarly, while some studies have demonstrated an association of GERD with increasing age, other studies have not.³⁰ In our present study, we found that increasing age is associated with increased odds for GERD symptoms up to a point, after which the risk decreases. Namely, when compared to 18–29 year olds, those 30–49 years of age have a higher prevalence of troublesome, Montreal-defined GERD symptoms, while those aged 60 years have a lower prevalence. As for race/ethnicity, there are also mixed findings. One study showed that blacks may experience more heartburn and Asians less heartburn as compared to whites,³³ while another study demonstrated no difference in GERD prevalence among blacks and whites.⁸ Although our study confirmed that Asians have a lower prevalence of GERD symptoms, our finding that GERD is also less common among non-Hispanic blacks vs. non-Hispanic whites is counter to prior findings.^{8, 33} Further research examining the etiologies behind disparities in GERD symptoms with age, gender, and race/ethnicity are needed.

Prior studies have demonstrated a higher prevalence of GERD among those with IBS^{34–36} and diabetes,^{37–39} which was confirmed with our study. We also found that those with IBS and diabetes have more severe GERD symptoms as measured by NIH PROMIS vs. those without the disorders. Moreover, we noted a higher prevalence of GERD symptoms among those with other comorbidities, most of which have not been previously reported or rigorously studied: Crohn's disease, endometriosis, and thyroid disease. Individuals with these diagnoses also have higher GERD PROMIS scores.

Aside from determining the prevalence and predictors of GERD symptoms, we also systematically assessed medication use. For those managing their condition with daily PPIs, we noted that 54% still have persistent GERD symptoms, which is comparable to previous observational estimates in primary care and community-based settings (45%, range 30% to 60%).⁶ With respect to independent predictors of PPI-refractory GERD symptoms, we found that Latinos are 2.44-times more likely to have persistent symptoms while on PPIs when compared to non-Hispanic whites. The reason behind this finding is unclear but may be secondary to physiologic or even cultural etiologies. Women⁶ and those with IBS⁴⁰ have been previously noted to be more likely to have PPI-refractory GERD, which our study confirmed. Associations have also been found between PPI-refractory symptoms and stress,⁴¹ anxiety, somatization, and functional GI disorders.^{42, 43} The increased prevalence of

functional and psychosomatic disorders among women may account in part for their increased odds of persistent GERD symptoms while on PPIs as seen in our study.⁴³ In regards to age, a Japanese study found that older age was more associated with PPI-resistance,⁴⁴ which is contrary to our findings. The higher prevalence of PPI-refractory GERD symptoms among younger individuals in our population may again be explained by the higher prevalence of somatization and functional disorders among this group,⁴³ where PPIs are unlikely to improve esophageal symptoms. While the degree to which our findings reflect inadequate acid suppression from PPIs vs. representing a surrogate for true underlying functional disease or non-acid reflux remains unclear, our results nonetheless demonstrate the need for further research and development of novel therapies for those with PPI-refractory GERD symptoms. Preliminary data has shown benefit with the potassium competitive acid blocker vonaprazan^{45, 46} as well as gastric-retained bile acid sequestrants.^{47, 48}

This study has strengths and limitations. The National GI Survey is among the largest US population-based studies focused on GI symptoms. We have information on more than 71,000 participants, with more than 32,000 individuals who reported ever experiencing GERD symptoms and nearly 1,900 individuals who reported PPI-refractory GERD symptoms in the last week. Another strength is our use of a novel online digital health tool that employs validated NIH PROMIS item banks and GERD-specific questions to systematically gather comprehensive information from respondents.^{16, 19, 49} This digital platform also allowed us to efficiently recruit a large, highly diverse, representative population in a very short period of time.

However, the online collection of data can also be considered a limitation. As the data were based on individuals' responses to an online survey, there are concerns in regard to generalizability, particularly among middle aged and elderly individuals with poor access to the Internet and/or limited computer skills. Our study may also have selected for older individuals who were more functional and independent. Of note, though, the Pew Research Institute reports that 82% and 63% of those 50–64 and 65 years old, respectively, used the Internet in 2015.⁵⁰ Nevertheless, our survey may have underestimated the prevalence of GERD and PPI-refractory GERD symptoms among older individuals. Conversely, our description of the study as a “GI Survey” to potential respondents may have led to an overestimation of GERD symptom prevalence, as those without GI issues may have opted to not complete the survey. We attempted to minimize participation bias by incentivizing users through Cint's reward system to fully complete the survey. Our results are also largely consistent with prior population-based studies, supporting the validity of our findings. We also would not have expected this to impact our regression analyses, as it is unlikely that there are systematic differences between survey responders and non-responders with GERD symptoms.

Additionally, we were not able to confirm pathologic reflux with esophageal pH monitoring, but instead relied on cardinal symptoms reported by respondents. Our survey methodology may have therefore led to misclassification of which respondents truly did or did not have objective GERD; however, any discrepancies would be consistent with misclassifications made in clinical practice where a diagnosis of GERD is typically based on patient-reported

symptoms without confirmatory, objective pH or impedance testing. Along the same lines, there may have been misclassification as our GI symptom screener question solely defined GERD as “heartburn, acid reflux, or gastroesophageal reflux” and did not specifically mention regurgitation. While some respondents may have equated “gastroesophageal reflux” with regurgitation, we nonetheless may have underestimated the prevalence of GERD, particularly for those who only experience regurgitation symptoms. Another limitation is that we did not assess whether respondents were taking PPIs correctly (i.e., 30–60 minutes before a meal), whether use of the PPI was guided by a physician or was self-administered (i.e., over-the-counter), or if they engaged in lifestyle modifications; this may have led to an overestimation of PPI-refractory symptoms. Finally, our study did not collect data on some demographic and lifestyle factors that can impact GERD symptom prevalence, such as body mass index, waist circumference, and alcohol and tobacco use; this will be addressed in our forthcoming National GI Survey 2. We also did not examine the impact of GERD symptoms on quality of life or healthcare utilization, as the primary goal of the National GI Survey was to assess the prevalence and distribution of the 8 cardinal GI symptoms. Further research updating our understanding of the burden imposed by GERD is warranted.

In conclusion, in this large population-based survey of community-dwelling Americans, we found that GERD symptoms are very common, with 2 of 5 having ever had such symptoms in the past and 1 of 3 experiencing symptoms in the past week. We also found an uneven distribution of GERD symptoms, as women, non-Hispanic whites, and those with comorbidities such as IBS, Crohn’s disease, diabetes, and endometriosis, among others, are more likely to be symptomatic. Additionally, we noted that more than half of those on daily PPI therapy continue to experience persistent heartburn and/or regurgitation symptoms. Due to the significant impact of GERD on quality of life and its considerable economic burden, further research is needed to further explore these associations as well as guide the development of novel therapies for those with PPI-refractory GERD symptoms.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

GRANT SUPPORT:

This study was funded by Ironwood Pharmaceuticals. The study sponsor did not have a role in the collection, analysis, or interpretation of data, or drafting of the manuscript. The Cedars-Sinai Center for Outcomes Research and Education (CS-CORE) is supported by The Marc and Sheri Rapaport Fund for Digital Health Sciences & Precision Health. Christopher V. Almario was supported by a career development award from the American College of Gastroenterology. Christopher V. Almario and Brennan M.R. Spiegel are supported by a NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881.

ABBREVIATIONS:

AEGIS	Automated Evaluation of Gastrointestinal Symptoms
CI	confidence interval
GERD	gastroesophageal reflux disease
GI	gastrointestinal

IBS	irritable bowel syndrome
NIH	National Institutes of Health
OR	odds ratio
PPI	proton pump inhibitor
PROMIS	Patient-Reported Outcomes Measurement Information System
PW	population-weighted

REFERENCES

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900–20; quiz 1943. [PubMed: 16928254]
2. Eslick GD, Talley NJ. Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life—a population-based study. *J Clin Gastroenterol* 2009;43:111–7. [PubMed: 18838922]
3. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. *Am J Gastroenterol* 2003;98:S8–s14. [PubMed: 12644026]
4. Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. *Am J Med* 1998;104:252–8. [PubMed: 9552088]
5. Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. *Gastroenterology* 2019;156:254–272.e11. [PubMed: 30315778]
6. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. *Aliment Pharmacol Ther* 2010;32:720–37. [PubMed: 20662774]
7. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut* 2014;63:871–80. [PubMed: 23853213]
8. El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. *Gastroenterology* 2004;126:1692–9. [PubMed: 15188164]
9. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. *Clin Gastroenterol Hepatol* 2005;3:543–52. [PubMed: 15952096]
10. The Henry J. Kaiser Family Foundation. Population distribution by race/ethnicity. 2017 [cited 2019 June 26]; Available from: <http://kff.org/other/state-indicator/distribution-by-raceethnicity/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D>.
11. Neumann CS, Cooper BT. Ethnic differences in gastro-oesophageal reflux disease. *Eur J Gastroenterol Hepatol* 1999;11:735–9. [PubMed: 10445793]
12. Almario CV, Almario AA, Cunningham ME, et al. Old farts - fact or fiction? Results from a population-based survey of 16,000 Americans examining the association between age and flatus. *Clin Gastroenterol Hepatol* 2017;15:1308–1310. [PubMed: 28344066]
13. Almario CV, Ballal ML, Chey WD, et al. Burden of gastrointestinal symptoms in the United States: results of a nationally representative survey of over 71,000 Americans. *Am J Gastroenterol* 2018;113:1701–1710. [PubMed: 30323268]
14. Menees SB, Almario CV, Spiegel BMR, et al. Prevalence of and factors associated with fecal incontinence: results from a population-based survey. *Gastroenterology* 2018;154:1672–1681.e3. [PubMed: 29408460]
15. Shah ED, Almario CV, Spiegel BMR, et al. Lower and upper gastrointestinal symptoms differ between individuals with irritable bowel syndrome with constipation or chronic idiopathic constipation. *J Neurogastroenterol Motil* 2018;24:299–306. [PubMed: 29605985]

16. Almario CV, Chey W, Kaung A, et al. Computer-generated vs. physician-documented history of present illness (HPI): results of a blinded comparison. *Am J Gastroenterol* 2015;110:170–9. [PubMed: 25461620]
17. Nagaraja V, Hays RD, Khanna PP, et al. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. *Arthritis Care Res (Hoboken)* 2014;66:1725–30. [PubMed: 24692332]
18. Spiegel BM. Patient-reported outcomes in gastroenterology: clinical and research applications. *J Neurogastroenterol Motil* 2013;19:137–48. [PubMed: 23667745]
19. Spiegel BM, Hays RD, Bolus R, et al. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. *Am J Gastroenterol* 2014;109:1804–14. [PubMed: 25199473]
20. HealthMeasures. Obtain & administer measures. 2018 [cited 2018 July 17]; Available from: <http://www.healthmeasures.net/explore-measurement-systems/promis/obtain-administer-measures>.
21. Howden LM, Meyer JA. Age and sex composition: 2010. 2011 [cited 2016 September 13]; Available from: <http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf>.
22. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. *Clin Gastroenterol Hepatol* 2007;5:17–26. [PubMed: 17142109]
23. Hales CM, Fryar CD, Carroll MD, et al. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007–2008 to 2015–2016. *JAMA* 2018;319:1723–1725. [PubMed: 29570750]
24. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. *JAMA* 2010;303:235–241. [PubMed: 20071471]
25. El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. *Am J Gastroenterol* 2005;100:1243–50. [PubMed: 15929752]
26. Locke GR 3rd, Talley NJ, Fett SL, et al. Risk factors associated with symptoms of gastroesophageal reflux. *Am J Med* 1999;106:642–9. [PubMed: 10378622]
27. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. *Am J Gastroenterol* 2006;101:2619–28. [PubMed: 16952280]
28. He J, Ma X, Zhao Y, et al. A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China. *BMC Gastroenterol* 2010;10:94. [PubMed: 20707933]
29. Ohara S, Kawano T, Kusano M, et al. Survey on the prevalence of GERD and FD based on the Montreal definition and the Rome III criteria among patients presenting with epigastric symptoms in Japan. *J Gastroenterol* 2011;46:603–11. [PubMed: 21359521]
30. Rubenstein JH, Chen JW. Epidemiology of gastroesophageal reflux disease. *Gastroenterol Clin North Am* 2014;43:1–14. [PubMed: 24503355]
31. Yaseri HF. Gender is a risk factor in patients with gastroesophageal reflux disease. *Med J Islam Repub Iran* 2017;31:58. [PubMed: 29445687]
32. Kim YS, Kim N, Kim GH. Sex and gender differences in gastroesophageal reflux disease. *J Neurogastroenterol Motil* 2016;22:575–588. [PubMed: 27703114]
33. Spechler SJ, Jain SK, Tendler DA, et al. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2002;16:1795–800. [PubMed: 12269973]
34. Lee SY, Lee KJ, Kim SJ, et al. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. *Digestion* 2009;79:196–201. [PubMed: 19342860]
35. Talley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. *Am J Gastroenterol* 2003;98:2454–9. [PubMed: 14638348]
36. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? *Gastroenterology* 2002;122:1140–1156. [PubMed: 11910364]
37. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. *J Gastroenterol* 2009;44:518–534. [PubMed: 19365600]

38. Natalini J, Palit A, Sankineni A, et al. Diabetes mellitus is an independent risk for gastroesophageal reflux disease among urban African Americans. *Dis Esophagus* 2015;28:405–411. [PubMed: 24641690]
39. Sun X-M, Tan J-C, Zhu Y, et al. Association between diabetes mellitus and gastroesophageal reflux disease: a meta-analysis. *World J Gastroenterol* 2015;21:3085. [PubMed: 25780309]
40. Monnikes H, Heading RC, Schmitt H, et al. Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. *World J Gastroenterol* 2011;17:3235–41. [PubMed: 21912473]
41. Wright CE, Ebrecht M, Mitchell R, et al. The effect of psychological stress on symptom severity and perception in patients with gastro-oesophageal reflux. *J Psychosom Res* 2005;59:415–24. [PubMed: 16310024]
42. Guillemot F, Ducrotte P, Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. *Gastroenterol Clin Biol* 2005;29:243–6. [PubMed: 15864173]
43. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Dig Dis Sci* 1993;38:1569–80. [PubMed: 8359066]
44. Takeshima F, Hashiguchi K, Onitsuka Y, et al. Clinical characteristics of patients with gastroesophageal reflux disease refractory to proton pump inhibitors and the effects of switching to 20 mg esomeprazole on reflux symptoms and quality of life. *Med Sci Monit* 2015;21:4111–21. [PubMed: 26719012]
45. Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. *Biomed Rep* 2017;6:175–180. [PubMed: 28357069]
46. Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. *Digestion* 2017;95:156–161. [PubMed: 28190016]
47. Vaezi M, Fass R, Reasner D, et al. IW-3718, a novel gastric-retentive bile acid sequestrant, improved symptoms of refractory GERD in a double-blind, placebo-controlled phase 2a study. *American Journal of Gastroenterology* 2015;110.
48. Vaezi MF, Fass R, Vakil N, et al. 875-IW-3718, a novel gastric-retentive bile acid sequestrant, improved heartburn and regurgitation symptoms in patients with persistent GERD despite PPI treatment: a double-blind, placebo-controlled study. *Gastroenterology* 2018;154:S–174.
49. Almario CV, Chey WD, Iriana S, et al. Computer versus physician identification of gastrointestinal alarm features. *Int J Med Inform* 2015;84:1111–7. [PubMed: 26254875]
50. Pew Research Center. Internet/broadband fact sheet. 2017 [cited 7 Dec 2017]; Available from: <http://www.pewinternet.org/fact-sheet/internet-broadband/>.

WHAT YOU NEED TO KNOW

BACKGROUND AND CONTEXT:

There are few data on the prevalence of gastroesophageal reflux disease (GERD) symptoms in the United States.

NEW FINDINGS:

A population-based survey found GERD symptoms to be common: 44.1% of participants reported having had GERD symptoms in the past and 30.9% reported having GERD symptoms in the last week. Half of users of proton pump inhibitors have persistent symptoms.

LIMITATIONS:

These findings are based on a survey completed by patients; results could be subject to bias.

IMPACT:

Given the significant effects of GERD on quality of life, further research and development of new therapies are needed for patients with proton pump inhibitor-refractory GERD symptoms.

TABLE 1.

National GI Survey participant demographics (N=71,812).

Variable	n	Actual %	Population-weighted % ^a
Age:			
18–29 y	23,962	33.4%	26.5%
30–39 y	19,284	26.9%	20.8%
40–49 y	11,854	16.5%	15.5%
50–59 y	10,808	15.1%	15.6%
60 y	5,904	8.2%	21.5%
Gender:			
Female	42,696	59.5%	51.0%
Male	29,116	40.5%	49.0%
Race/ethnicity:			
Non-Hispanic white	50,943	70.9%	62.0%
Non-Hispanic black	6,353	8.9%	12.0%
Latino	8,255	11.5%	18.0%
Asian	3,914	5.5%	6.0%
Other	2,347	3.3%	2.0%
Education level:			
Did not graduate high school	2,862	4.0%	4.2%
High school graduate	15,295	21.3%	21.5%
Some college	22,282	31.0%	30.9%
College graduate	24,020	33.4%	32.7%
Graduate degree	7,353	10.2%	10.7%
Marital status:			
Single	19,120	26.6%	24.5%
Divorced, separated, or widowed	8,592	12.0%	16.1%
Married or in long term relationship	44,100	61.4%	59.4%
Employment status:			
Unemployed ^b	24,680	34.4%	40.3%
Employed or full-time student	47,132	65.6%	59.7%
Total household income:			
\$0–50,000	35,725	49.7%	50.0%
\$50,001–100,000	22,226	31.0%	30.7%
\$100,001–200,000	7,582	10.6%	10.3%
\$200,001	1,110	1.5%	1.7%
Prefer not to say	5,169	7.2%	7.4%
Irritable bowel syndrome	2,958	4.1%	3.8%
Chronic idiopathic constipation	276	0.4%	0.4%
Gastrointestinal cancer	407	0.6%	0.8%
Celiac disease	755	1.1%	0.9%
Cirrhosis	450	0.6%	0.7%

Variable	n	Actual %	Population-weighted % ^a
Crohn's disease	553	0.8%	0.8%
Ulcerative colitis	627	0.9%	1.1%
Diabetes	4,508	6.3%	8.6%
Endometriosis	1,680	2.3%	2.0%
Gallstones	3,058	4.3%	4.5%
HIV/AIDS	233	0.3%	0.4%
Pancreatitis	539	0.8%	0.8%
Peptic ulcer disease	1,172	1.6%	1.7%
Thyroid disease	3,483	4.9%	5.2%

^aPopulation weights based on recent US Census data for age, sex, and race/ethnicity were applied to the sample data in order to produce population estimates; the actual weights used in the analyses were previously described elsewhere.^{13, 14}

^bIncludes those who reported being unemployed, on disability, on leave of absence from work, retired, or homemaker.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 2. Predictors of GERD symptoms in past 7 days and GERD as determined by a modified Montreal definition (N=71,812).

Variable	Had GERD symptoms in past 7 days (n=23,039)	OR [95% CI] ^a	Had GERD symptoms using modified Montreal definition (n=13,881) ^b	OR [95% CI] ^c
Age:		Reference		reference
18–29 y	6,215 (25.2%)		3,875 (15.6%)	1.33 [1.25–1.40]
30–39 y	6,660 (33.7%)	1.34 [1.28–1.40]	4,284 (21.7%)	1.26 [1.17–1.34]
40–49 y	4,364 (35.3%)	1.40 [1.32–1.49]	2,657 (21.4%)	1.03 [0.95–1.10]
50–59 y	3,945 (35.3%)	1.33 [1.25–1.42]	2,180 (19.2%)	0.68 [0.57–0.81]
60 y	1,855 (28.9%)	0.98 [0.86–1.11]	885 (13.9%)	
Gender:				
Female	14,575 (33.0%)	reference	8,979 (19.8%)	reference
Male	8,464 (28.7%)	0.88 [0.83–0.93]	4,902 (16.0%)	0.84 [0.79–0.90]
Race/ethnicity:				
Non-Hispanic white	17,708 (33.8%)	reference	10,614 (19.4%)	reference
Non-Hispanic black	1,413 (22.6%)	0.62 [0.57–0.69]	860 (13.0%)	0.68 [0.61–0.76]
Latino	2,425 (30.8%)	0.89 [0.79–1.00]	1,569 (19.5%)	1.02 [0.89–1.16]
Asian	805 (19.2%)	0.53 [0.46–0.60]	411 (9.1%)	0.48 [0.41–0.56]
Other	688 (28.2%)	0.81 [0.72–0.92]	427 (17.5%)	0.94 [0.81–1.10]
Education level:				
Did not graduate high school	692 (21.1%)	reference	487 (14.6%)	reference
High school graduate	4,906 (31.0%)	1.43 [1.24–1.64]	3,078 (18.8%)	1.16 [1.00–1.35]
Some college	7,526 (33.0%)	1.52 [1.32–1.74]	4,652 (19.2%)	1.15 [1.00–1.33]
College graduate	7,779 (30.9%)	1.33 [1.16–1.53]	4,491 (17.5%)	0.99 [0.85–1.15]
Graduate degree	2,136 (28.5%)	1.20 [1.03–1.41]	1,173 (15.6%)	0.90 [0.74–1.09]
Marital status:				
Single	4,619 (23.5%)	reference	2,665 (13.3%)	reference
Divorced, separated, or widowed	2,957 (32.2%)	1.27 [1.14–1.42]	1,828 (18.3%)	1.39 [1.23–1.57]
Married or in long term relationship	15,463 (33.6%)	1.35 [1.28–1.43]	9,388 (19.8%)	1.43 [1.34–1.52]
Employment status:				
Unemployed ^c	8,390 (31.1%)	reference	5,165 (17.6%)	reference

Variable	Had GERD symptoms in past 7 days (n=23,039)	OR [95% CI] ^a	Had GERD symptoms using modified Montreal definition (n=13,881) ^b	OR [95% CI] ^d
Employed or full-time student	14,649 (30.8%)	1.00 [0.94–1.07]	8,716 (18.2%)	1.02 [0.94–1.11]
Total household income:		reference		reference
\$0–50,000	11,535 (30.4%)		7,155 (18.2%)	
\$50,001–100,000	7,775 (34.5%)	1.12 [1.05–1.19]	4,661 (20.2%)	1.10 [1.02–1.18]
\$100,001–200,000	2,498 (32.4%)	1.01 [0.93–1.10]	1,400 (18.1%)	0.95 [0.86–1.05]
\$200,001	276 (25.3%)	0.81 [0.66–0.99]	162 (14.1%)	0.80 [0.64–0.99]
Prefer not to say	955 (18.6%)	0.57 [0.49–0.68]	503 (8.0%)	0.43 [0.38–0.50]
Irritable bowel syndrome	1,590 (54.7%)	2.19 [1.85–2.59]	1,103 (36.3%)	2.11 [1.76–2.54]
Chronic idiopathic constipation	135 (44.4%)	1.24 [0.78–1.99]	110 (35.0%)	1.66 [0.99–2.79]
Gastrointestinal cancer	123 (28.9%)	0.85 [0.43–1.67]	91 (22.2%)	1.17 [0.49–2.78]
Celiac disease	268 (33.8%)	1.00 [0.82–1.22]	190 (24.2%)	1.11 [0.89–1.39]
Cirrhosis	169 (37.4%)	1.22 [0.89–1.69]	132 (29.4%)	1.60 [1.11–2.31]
Crohn's disease	232 (42.2%)	1.34 [1.05–1.70]	183 (32.6%)	1.69 [1.31–2.18]
Ulcerative colitis	257 (43.4%)	1.50 [0.89–2.52]	176 (26.3%)	1.34 [0.76–2.36]
Diabetes	1,806 (35.3%)	1.16 [1.04–1.30]	1,139 (20.0%)	1.14 [1.01–1.29]
Endometriosis	808 (44.6%)	1.21 [1.05–1.39]	561 (30.5%)	1.31 [1.13–1.51]
Gallstones	1,536 (48.4%)	1.63 [1.40–1.90]	1,031 (31.1%)	1.63 [1.37–1.94]
HIV/AIDS	67 (28.5%)	0.83 [0.45–1.52]	45 (17.8%)	0.77 [0.32–1.81]
Pancreatitis	270 (44.7%)	1.20 [0.94–1.53]	194 (30.6%)	1.28 [1.00–1.64]
Peptic ulcer disease	743 (57.0%)	2.33 [1.76–3.07]	530 (38.1%)	2.23 [1.79–2.77]
Thyroid disease	1,500 (40.6%)	1.25 [1.10–1.42]	974 (25.0%)	1.31 [1.14–1.49]

Data are presented as n (population-weighted %).

CI, confidence interval; GERD, gastroesophageal reflux disease; OR, odds ratio.

^aThe logistic regression model included all variables listed in the table above.

^bDefined as heartburn or regurgitation occurring 2 days in the last week.

^cIncludes those who reported being unemployed, on disability, on leave of absence from work, retired, or homemaker.

TABLE 3.Predictors of GERD severity among those symptomatic in the past week (n=19,435^a).

Variable	GERD PROMIS percentile score (0–100) ^b	β coefficient ^c	p-value ^c
Age:			
18–29 y	56.7 [55.9–57.5]	reference	reference
30–39 y	55.6 [54.8–56.3]	–2.52	<.001
40–49 y	53.7 [52.7–54.7]	–5.96	<.001
50–59 y	48.6 [47.5–49.7]	–11.94	<.001
60 y	44.7 [41.6–47.7]	–16.14	<.001
Gender:			
Female	52.9 [51.9–53.8]	reference	reference
Male	50.6 [49.4–51.7]	–1.70	.01
Race/ethnicity:			
Non-Hispanic white	50.2 [49.7–50.8]	reference	reference
Non-Hispanic black	50.1 [47.5–52.8]	–0.25	.85
Latino	58.7 [55.5–61.8]	7.34	<.001
Asian	53.3 [50.0–56.6]	3.66	.02
Other	54.0 [51.2–56.9]	2.85	.06
Education level:			
Did not graduate high school	58.6 [55.5–61.6]	reference	reference
High school graduate	53.0 [51.5–54.6]	–3.88	.02
Some college	52.1 [50.8–53.3]	–5.53	.001
College graduate	51.2 [50.0–52.4]	–7.10	<.001
Graduate degree	49.0 [46.3–51.7]	–8.35	<.001
Marital status:			
Single	51.3 [50.2–52.4]	reference	reference
Divorced, separated, or widowed	49.5 [46.7–52.3]	3.11	.01
Married or in long term relationship	52.6 [51.8–53.4]	3.12	<.001
Employment status:			
Unemployed ^d	50.1 [48.8–51.4]	reference	reference
Employed or full-time student	53.1 [52.2–53.9]	1.20	.15
Total household income:			
\$0–50,000	52.8 [51.7–53.9]	reference	reference
\$50,001–100,000	52.3 [51.1–53.5]	0.28	.70
\$100,001–200,000	49.1 [47.6–50.6]	–2.17	.02
\$200,001	52.1 [45.4–58.7]	1.64	.56
Prefer not to say	44.4 [40.7–48.1]	–6.10	.002
Irritable bowel syndrome	60.5 [57.5–63.5]	7.66	<.001
Chronic idiopathic constipation	69.0 [60.9–77.2]	6.56	.07
Gastrointestinal cancer	73.8 [58.7–88.8]	11.88	.06
Celiac disease	68.7 [62.5–74.9]	5.81	.03

Variable	GERD PROMIS percentile score (0–100) ^b	β coefficient ^c	p-value ^c
Cirrhosis	73.9 [68.2–79.7]	11.67	<.001
Crohn's disease	69.5 [63.9–75.1]	8.30	<.001
Ulcerative colitis	58.3 [43.6–73.0]	4.09	.49
Diabetes	53.5 [51.3–55.7]	2.76	.02
Endometriosis	59.3 [56.7–61.9]	3.91	.004
Gallstones	55.2 [52.7–57.7]	1.77	.18
HIV/AIDS	57.0 [45.2–68.8]	6.36	.37
Pancreatitis	58.9 [53.7–64.1]	1.61	.50
Peptic ulcer disease	57.3 [54.1–60.5]	2.88	.07
Thyroid disease	54.9 [52.6–57.2]	3.45	.006
PPI use:			
Not taking	49.9 [49.1–50.7]	reference	reference
Less than daily use	65.3 [62.5–68.1]	14.21	<.001
Daily use	55.2 [53.1–57.3]	8.84	<.001
Unknown frequency of use	60.2 [43.5–76.9]	–1.82	.81
Histamine-2 receptor blocker use:			
Not taking	50.8 [50.0–51.5]	reference	reference
Less than daily use	60.6 [57.3–63.8]	9.35	<.001
Daily use	60.8 [57.1–64.5]	12.46	<.001
Unknown frequency of use	68.4 [58.3–78.6]	14.63	.01
Antacid use:			
Not taking	51.5 [50.7–52.2]	reference	reference
Less than daily use	52.6 [49.9–55.2]	4.44	<.001
Daily use	63.2 [59.6–66.8]	14.50	<.001
Unknown frequency of use	59.5 [47.4–71.6]	3.21	.56

Data are presented as survey-weighted mean [95% confidence interval].

GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor; PROMIS, Patient-Reported Outcome Measurement Information System.

^a3,604 out of 23,039 individuals with GERD in the past 7 days had missing medication data, so the analyses was performed among 19,435 respondents.

^bHigher score equals more severe symptoms.

^cThe linear regression model included all variables listed in the table above.

^dIncludes those who reported being unemployed, on disability, on leave of absence from work, retired, or homemaker.

TABLE 4.

GERD medication frequency of use (n=9,234).

Frequency of use	PPI (n=4,935)	Histamine-2 receptor blocker (n=2,286)	Antacids (n=2,370)	Other (n=217)
Every few months	170 (3.2%)	138 (6.0%)	160 (6.8%)	14 (4.9%)
Few times a month	266 (5.0%)	225 (10.9%)	375 (16.0%)	17 (8.7%)
Once a week	383 (7.4%)	249 (10.7%)	317 (12.0%)	9 (4.1%)
2–3 days/week	521 (9.6%)	438 (18.9%)	612 (29.6%)	37 (15.6%)
4–6 days/week	351 (6.5%)	254 (11.3%)	355 (13.5%)	14 (4.7%)
Daily	3,229 (68.1%)	956 (41.0%)	513 (20.3%)	116 (59.3%)
Unknown	15 (0.2%)	26 (1.4%)	38 (1.9%)	10 (2.8%)

Data are presented as n (population-weighted %).

GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 5.

Predictors of persistent GERD symptoms among those taking a daily PPI (n=3,229).

Variable	Persistent GERD symptoms while on daily PPI ^a (n=1,858)	OR [95% CI] ^b
Age:		
18–29 y	213 (64.9%)	reference
30–39 y	451 (69.2%)	1.18 [0.86–1.63]
40–49 y	448 (60.3%)	0.76 [0.56–1.05]
50–59 y	481 (52.3%)	0.56 [0.40–0.77]
60 y	265 (45.6%)	0.46 [0.31–0.69]
Gender:		
Female	1,270 (57.6%)	reference
Male	588 (49.4%)	0.78 [0.62–0.99]
Race/ethnicity:		
Non-Hispanic white	1,544 (51.1%)	reference
Non-Hispanic black	92 (45.9%)	0.83 [0.51–1.34]
Latino	150 (72.8%)	2.44 [1.42–4.20]
Asian	22 (62.8%)	1.13 [0.47–2.69]
Other	50 (51.7%)	0.92 [0.53–1.59]
Education level:		
Did not graduate high school	66 (64.7%)	reference
High school graduate	444 (53.9%)	0.66 [0.33–1.29]
Some college	634 (55.7%)	0.73 [0.37–1.41]
College graduate	550 (51.9%)	0.62 [0.32–1.22]
Graduate degree	164 (52.1%)	0.67 [0.30–1.46]
Marital status:		
Single	245 (52.4%)	reference
Divorced, separated, or widowed	349 (55.9%)	1.55 [1.05–2.29]
Married or in long term relationship	1,264 (53.7%)	1.37 [1.02–1.84]
Employment status:		
Unemployed ^c	923 (49.7%)	reference
Employed or full-time student	935 (59.9%)	1.27 [0.96–1.67]
Total household income:		
\$0–50,000	1,013 (57.5%)	reference
\$50,001–100,000	584 (53.5%)	0.81 [0.61–1.07]
\$100,001–200,000	180 (48.7%)	0.65 [0.45–0.93]
\$200,001	24 (57.4%)	0.94 [0.40–2.22]
Prefer not to say	57 (33.9%)	0.41 [0.24–0.69]
Irritable bowel syndrome	263 (62.8%)	1.39 [1.03–1.88]
Chronic idiopathic constipation	41 (64.7%)	1.17 [0.45–3.05]
Gastrointestinal cancer	12 (23.7%)	0.21 [0.09–0.48]
Celiac disease	25 (64.2%)	0.98 [0.39–2.48]
Cirrhosis	20 (44.6%)	0.68 [0.31–1.48]

Variable	Persistent GERD symptoms while on daily PPI ^a (n=1,858)	OR [95% CI] ^b
Crohn's disease	47 (86.1%)	5.16 [2.22–12.00]
Ulcerative colitis	35 (42.0%)	0.49 [0.28–0.87]
Diabetes	254 (48.9%)	0.83 [0.61–1.14]
Endometriosis	120 (57.1%)	0.95 [0.60–1.51]
Gallstones	226 (54.9%)	1.02 [0.68–1.51]
HIV/AIDS	10 (54.9%)	2.20 [0.17–28.97]
Pancreatitis	50 (58.7%)	1.27 [0.65–2.46]
Peptic ulcer disease	157 (60.1%)	1.19 [0.82–1.73]
Thyroid disease	215 (55.3%)	1.23 [0.86–1.75]
Histamine-2 receptor blocker use:		
Not taking	1,789 (53.5%)	reference
Less than daily use	21 (71.1%)	1.52 [0.57–4.09]
Daily use	32 (74.2%)	2.37 [0.96–5.86]
Unknown frequency of use	16 (70.4%)	2.06 [0.66–6.41]
Antacid use:		
Not taking	1,789 (53.6%)	reference
Less than daily use	33 (56.7%)	1.30 [0.57–2.96]
Daily use	20 (72.4%)	1.81 [0.67–4.92]
Unknown frequency of use	16 (97.2%)	29.79 [3.46–256.57]

Data are presented as n (population-weighted %).

CI, confidence interval; GERD, gastroesophageal reflux disease; OR, odds ratio; PPI, proton pump inhibitor.

^aDefined as heartburn or regurgitation occurring ≥ 2 days in the last week among those on a daily PPI.

^bThe logistic regression model included all variables listed in the table above.

^cIncludes those who reported being unemployed, on disability, on leave of absence from work, retired, or homemaker.